there is concern that Dexrazoxane reduces the efficacy of the cancer treatment, albeit cardio protective.
On the flip side Zantrene is cardio protective, anti cancer as a single agent and synergises with Doxo. Not only Anthracyclines but also Proteasome inhibitors e.g. Krypolis.
There are a few other cardio protective anti cancer treatments, either off patent so won’t be pursued or in research phases so many years behind Race.
Thus Race is maintaining a first-in-class best-in-class advantage.
Ann: Appendix 4E & Annual Report, page-27
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.74 |
Change
0.040(2.35%) |
Mkt cap ! $295.4M | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.82 | $1.72 | $182.5K | 104.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1977 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 111 | 2 |
View Market Depth
| Last trade - 12.57pm 08/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |